Hu Gan Tang ameliorates metabolic-associated fatty liver disease by inhibiting ferroptosis through the Nrf2/GPX4 pathway
Journal of Ethnopharmacology · 2025-09 · 353 · 120342
DOI: 10.1016/j.jep.2025.120342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ethnopharmacology, 2025-09. Verfasst von Lihua Cui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Integrative Medicine for Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, 300100, China; Tianjin …. Hauptthemen laut MEDLINE: Ferroptosis, NF-E2-Related Factor 2, Drugs, Chinese Herbal, Phospholipid Hydroperoxide Glutathione Peroxidase. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: TianJin Education Committee, Tianjin Municipal Health Commission.
Abstract (Originalsprache)
ETHNOPHARMACOLOGICAL RELEVANCE: Hu Gan Tang (HGT), a modified formulation of the traditional Chinese medicine "Si jun zi", is based on the principle of "strengthening the spleen, resolving dampness, and purging turbidity" for the treatment of metabolic-associated fatty liver disease (MAFLD). HGT has shown efficacy in alleviating liver damage in MAFLD patients. Nevertheless, its underlying molecular mechanisms remain unexplored. AIM OF THE STUDY: This study aimed to investigate the hepatoprotective effects of HGT against MAFLD by regulating hepatic ferroptosis in both in vivo and in vitro models. MATERIALS AND METHODS: The MAFLD rat model was established through exposure to a high-fat diet (HFD). HGT was administered intragastrically for eight consecutive weeks. Histological and biochemical tests were conducted to assess liver damage. In an in vitro study, HepG2 cells were incubated with free fatty acids (FFAs) in the presence or absence of HGT drug-containing serum. Ferroptosis-related parameters, including intracellular Fe2+ levels, MDA and SOD levels, ROS levels, and the expression levels of ferroptosis-related proteins and modulators, were quantified both in vivo and in vitro. Additionally, Nrf2 inhibitor (ML385) and GPX4 inhibitor (RSL3) were utilized to validate the underlying mechanisms of HGT's hepatoprotective effects. RESULTS: The results demonstrated that HGT alleviated liver injury and reduced lipid accumulation. Furthermore, HGT suppressed oxidative stress by decreasing MDA and ROS levels while increasing SOD levels in both in vivo and in vitro settings. Additionally, HGT inhibited ferroptosis by reducing Fe2+ accumulation, upregulating xCT, GPX4, and FTH1 expression, and enhancing nuclear Nrf2 expression in liver tissue and steatotic HepG2 cells. Further research revealed that HGT reduced lipid accumulation, suppressed oxidative stress, and alleviated ferroptosis in hepatocytes by activating the Nrf2/GPX4 signaling pathway. These findings provide a novel therapeutic mechanism for HGT in ameliorating MAFLD. CONCLUSION: HGT significantly suppresses hepatic ferroptosis, reduces oxidative stress, diminishes lipid accumulation, and ameliorates liver damage by activating the Nrf2/GPX4 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Integrative Medicine for Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, 300100, China; Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and IT…
- Hospital of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 300100, China. Electronic address: lumeihua860419@sina.com.
- Hospital of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 300100, China. Electronic address: lw13283709195@163.com.
- Hospital of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 300100, China. Electronic address: 2528552935@qq.com.
- Hospital of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 300100, China; Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM Repair,…
Förderung
- TianJin Education Committee
- Tianjin Municipal Health Commission
Zitieren
APA
Cui, L., Lu, M., Li, W., Yin, Y., Li, C., & Chen, M. (2025). Hu Gan Tang ameliorates metabolic-associated fatty liver disease by inhibiting ferroptosis through the Nrf2/GPX4 pathway. Journal of Ethnopharmacology, 353, 120342. https://doi.org/10.1016/j.jep.2025.120342
Vancouver
Cui L, Lu M, Li W, Yin Y, Li C, Chen M. Hu Gan Tang ameliorates metabolic-associated fatty liver disease by inhibiting ferroptosis through the Nrf2/GPX4 pathway. Journal of Ethnopharmacology. 2025;353:120342. doi:10.1016/j.jep.2025.120342
BibTeX
@article{Cui2025,
author = {Cui, Lihua and Lu, Meihua and Li, Wen and Yin, Yao and Li, Caixia and Chen, Ming},
title = {Hu Gan Tang ameliorates metabolic-associated fatty liver disease by inhibiting ferroptosis through the Nrf2/GPX4 pathway},
journal = {Journal of Ethnopharmacology},
year = {2025},
volume = {353},
pages = {120342},
doi = {10.1016/j.jep.2025.120342}
}
EUVIMED